| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Myriad Genetics (NASDAQ:MYGN) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Myriad Genetics beat estimated earnings by 300.0%, reporting an EPS of $0.04 versus an estimate of $0.01.
Revenue was up $18.80 million from the same period last year.
Last quarter the company beat on EPS by $0.05 which was followed by a 9.0% increase in the share price the next day.
Here's a look at Myriad Genetics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.08 | -0.19 | -0.16 |
| EPS Actual | -0.03 | -0.08 | -0.21 | -0.12 |
| Revenue Estimate | 179.25M | 187.13M | 171.55M | 169.46M |
| Revenue Actual | 191.90M | 183.50M | 181.20M | 177.80M |
To track all earnings releases for Myriad Genetics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MYGN
